Australia is facing a shortage of tocilizumab (Actemra) until at least September due to a surge in global demand for its use in treating COVID-19 patients. Roche Australia has written to rheumatologists to advise that as of July 5 there was “an immediate shortage” of Actemra IV 200mg in Australia, and the company anticipated a ...
Tocilizumab shortage in Australia as WHO approves use for COVID-19
By Julie Lambert
12 Jul 2021